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Recent data in a nonhuman primate model showed that infants postnatally infected with Zika virus 
(ZIKV) were acutely susceptible to high viremia and neurological damage, suggesting the window 
of vulnerability extends beyond gestation. In this pilot study, we addressed the susceptibility of two 
infant rhesus macaques born healthy to dams infected with Zika virus during pregnancy. Passively 
acquired neutralizing antibody titers dropped below detection limits between 2 and 3 months of age, 
while binding antibodies remained detectable until viral infection at 5 months. Acute serum viremia 
was comparatively lower than adults infected with the same Brazilian isolate of ZIKV (n = 11 pregnant 
females, 4 males, and 4 non-pregnant females). Virus was never detected in cerebrospinal fluid nor 
in neural tissues at necropsy two weeks after infection. However, viral RNA was detected in lymph 
nodes, confirming some tissue dissemination. Though protection was not absolute and our study 
lacks an important comparison with postnatally infected infants born to naïve dams, our data suggest 
infants born healthy to infected mothers may harbor a modest but important level of protection from 
postnatally acquired ZIKV for several months after birth, an encouraging result given the potentially 
severe infection outcomes of this population.
Zika virus (ZIKV) emerged in Brazil in 2015 and maternal infection during pregnancy was astutely correlated 
with an increase in newborns with microcephaly1,2, a profound developmental defect that results in infants with 
reduced brain size and cognitive capacity. ZIKV was initially discovered in 1947 in the Zika forest of Uganda 
during surveillance for yellow fever virus3. Soon thereafter, it became clear that human infections with ZIKV in 
that region were not uncommon4,5 but disease associated with infection appeared to be minor and ZIKV became 
something of an afterthought. The emergence in Brazil and its association with both major and, more recently, 
less severe neurological consequences in congenitally-infected newborns6, collectively called “congenital Zika 
syndrome”, rapidly changed that perception. A profound research effort was subsequently launched to understand 
mechanisms of pathogenesis7,8, identify cellular receptors9–12 and targets9,12–16, to develop animal models17–23, and 
to develop and test vaccines24–29 and therapeutics23,30.
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Human brain development continues well after birth31 so it stands to reason that the risk of ZIKV associated 
neurological disease may extend for an unknown period of time after birth. Indeed, a recent study in nonhu-
man primate infants showed high peak viral loads and dissemination into multiple brain regions at two weeks 
post-infection and quantifiable neurological defects and cognitive impairment in infants infected in the first few 
months of life32.
Given the high incidence of ZIKV infection in several South and Central American countries during the 
height of the ZIKV epidemic, it is likely that a large number of babies without congenital infection or disease 
sequelae were born to infected mothers. The vulnerability of these infants to newly acquired infection after birth 
has not been addressed. A recent macaque study showed that fetal infection after subcutaneous inoculation of 
dams with ZIKV was efficient, with four of four fetuses showing evidence of infection33. Since not all infants 
exhibit detectable ZIKV disease when born to infected mothers, it remains unclear whether these infants remain 
uninfected and/or unaffected due to pre-existing passively acquired maternal antibodies, if they mount their own 
de novo anti-ZIKV immune responses in utero or soon after birth, or if infection can be limited and apathogenic 
for an unknown reason. Addressing these issues will be key to addressing the susceptibility of newborns to post-
natal ZIKV infection in areas with endemic for ZIKV transmission. During this study, we monitored antiviral 
antibody responses after birth in two infant macaques born to ZIKV infected dams and assessed the level of 
protection these responses might provide against postnatal infection. Upon infection at five months of age, both 
infants showed only modest levels of peripheral viremia and no virus detected in neurological tissues. These 
data suggest that being born to a ZIKV infected mother may confer a small but important level of immunity to 
postnatal infection.
Results
Infants born healthy with no evidence of viral infection. Both infants enrolled in this study were born 
via caesarean section at full term to dams infected in the third trimester as part of a previous study23. At the time 
of caesarean section, both dams had cleared serum virus but one dam exhibited a spike of amniotic fluid virus that 
remained detectable at the time of caesarean section (Fig. 1A). However, at birth, neither infant showed evidence 
of infection as measured in blood or cerebrospinal fluid (CSF) (Fig. 1B).
Despite no direct evidence of infection in the infants, we next assessed the possibility that infection had 
occurred in utero and induced neurological deficits. To do this, we used multiple defined testing parameters to 
compare the infants with seven control infants raised in the same manner and tested by the same technician. At 
15 days of age, both infants showed slightly elevated levels of state control, motor maturity and activity while one 
infant did not attend to the orientation test (Fig. 2A). At 16 and 20 weeks of age, both infants showed levels of 
cognitive abilities that were somewhat elevated while motor development was normal. The temperament of both 
infants was markedly calmer than controls (Fig. 2B). The small sample size negated any meaningful statistical 
analysis. These behavioral observations were exploratory and were designed to identify any overt abnormalities 
that might be explored in future studies and none were noted.
Viral dynamics in the infants. At approximately five months of age (148 days for F10, 155 days for F09), 
we inoculated both infants with the same dose (104 PFU), via the same subcutaneous route, of the same Brazilian 
isolate of ZIKV that their dams had been infected with. Peak viral load in infant F09 was approximately 20,000 
viral RNA copies per milliliter of plasma, which was completely cleared by day 5 post infection. F09 was the only 
animal in our studies to clear blood viral RNA prior to day 5. In infant F10, the viral load remained below 1,000 
copies per milliliter but remained detectable until day 7 (Fig. 3A). No virus was detected in CSF at any time point 
in either infant.
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Figure 1. Viral dynamics in the infants in this study and their dams. (A) Blood and amniotic fluid in two 
female macaques (dams of the infants in this study). Each animal was inoculated with ZIKV during early 
third trimester and monitored for infection until giving birth via cesarean section at full term (approximately 
gestational day 155). (B) Blood and CSF viral loads in the infants after birth and before postnatal viral infection. 
Neither infant had detectable virus in serum or CSF during the first two weeks of life. The limit of detection of 
approximately 15 copies per milliliter of plasma is shown as a horizontal line in both panels.
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For comparison, viral loads are shown from 11 pregnant females infected with the same stock of the 
same strain (Rio-U1/2016) of the virus at the same dose (104 pfu) and route (subcutaneous) (Fig. 3B) as well 
as four non-pregnant females (Fig. 3C) and four adult males (Fig. 3D) infected with the same dose and strain 
(Rio-U1/2016) of the virus, but that was cultured one additional passage in Vero cells. CSF samples are shown for 
all groups as well. Virus was not detected in CSF in our pregnant females but we note that CSF was sampled less 
frequently in the pregnant females due to safety concerns. Area under the curve (AUC) analyses was performed 
to assess the total viremia in these two infants relative to adults infected in our studies (Fig. 3E). At necropsy, we 
performed RT PCR for ZIKV RNA on serum, CSF, multiple brain regions (frontal cortex, parietal lobe, occipital 
lobe, temporal lobe, brain stem, optic nerve, cerebellum, choroid plexus, and subcortical white matter), and axil-
lary lymph nodes and virus was detected only in the axillary lymph in both animals (Fig. 3F).
Neither infant in this study showed signs of potential virus-induced pathology at necropsy. F10 harbored a 
choroid plexus cyst that resulted in unilateral hydrocephalus in the brain, but such cysts are common, are gener-
ally considered of little consequence and are not likely viral in origin.
Antibody responses. We next examined humoral responses in the infants to see if they might explain the 
strikingly low viral loads. We used a plaque reduction neutralization test (PRNT) to assess neutralizing antibodies 
in serum after birth and after infection in both infants. Both showed detectable levels of neutralization at birth, 
which quickly waned below the limit of detection by 2 to 3 months. Neutralizing antibodies reemerged after 
infection and continued to rise until euthanasia at 2 weeks post infection (Fig. 4A). To measure binding antibod-
ies, we employed a whole virion ELISA assay using plasma samples collected throughout the infants’ lives both 
before and after infection. Binding IgG titers decreased between birth and 3–4 months of age, consistent with the 
expected kinetics of passively-transferred maternal IgG, but remained detectable until viral inoculation at five 
months, and then rose after infection, similar to the neutralizing antibody titers (Fig. 4B).
Discussion
ZIKV reemerged in 2015 in South America and was quickly correlated with an increase in infants born with pro-
found neurological defects1,2. It’s not entirely clear what fraction of pregnant women that become infected with 
ZIKV during pregnancy transmit the virus to their developing fetus but consequences to the fetus can range from 
mild to severe. Additionally, nonhuman primate studies suggest that infants may remain susceptible to ZIKV 
induced disease even if infected after birth32, but the frequency and disease severity postnatal ZIKV infections in 
human infants remains to be fully examined34,35.
Given the high incidence of ZIKV in several countries during the height of the outbreak36, the relative abun-
dance of the most competent vector for ZIKV transmission, the mosquito Aedes aegypti, particularly in urban 
environments (Centers for Disease Control [CDC], 2017), it’s likely that many infants born healthy to infected 
mothers are themselves exposed to the virus via mosquito bite after birth. It is not clear if passively acquired 
maternal antibodies against ZIKV can offer some level of protection and for what period of time after birth. It is 
also not clear if infants exposed to the virus in utero, but born healthy and seemingly uninfected, may themselves 
have mounted de novo immune responses against the virus in utero. Induction of adaptive immune responses in 
utero is possible but few examples have been described. For example, functional, malaria-specific T cell responses 
have been detected in fetuses37. Further, infants are routinely vaccinated against hepatitis B virus within twenty 
four hours of birth, which has dramatically reduced the frequency of infant infection38. These data suggest a 
high level of immune competence very early in life. In the context of ZIKV, macaque data suggest that vertical 
transmission is quite common33 but, to date, there is no data suggesting these infants mount antiviral adaptive 
immune responses.
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Figure 2. Behavioral assessment of the infants from birth unitl postnatal ZIKV infection. Neurobehavioral 
scores for F09 and F10 and 7 controls. (A) The infants were assessed for behavioral abnormalities and test scores 
were measured at 15 days of age, as described in the text. F10 was not attentive during the test of orientation so 
was not assessed. For each category, scores for individual tests were averaged for analysis. (B) Each infant was 
likewise assessed for cognitive, motor, and temperament at sixteen and twenty weeks of age. Scores within a 
category were summed for analysis.
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Passively acquired maternal antibodies are fairly well described. Their magnitude, transmission efficiency in 
utero, and decay kinetics after birth have been described in the context of infection with and vaccination against 
several pathogens39,40. For instance, maternal anti-varicella-zoster virus (VSV) antibodies are readily detectable 
in infants born to mothers that were infected VSV earlier in life, but decline below the threshold of detection by 
4–5 months of age40. These kinetics are similar to the decay rate of binding and neutralizing anti-ZIKV antibodies 
in our study. Maternal antibodies to dengue virus (DENV) have also been described in newborns41–44 and may 
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Figure 3. Viral dynamics in the infants after postnatal infection along with adults in other studies. (A) Viral 
loads (serum and CSF) were assessed at days 0, 3, 5, 7, 10, and at necropsy on day 14 in both infants. Viral loads 
for eleven pregnant females (B) infected with the same dose and route of the same stock of virus, as well as four 
adult non-pregnant females (C), and four adult males (D) infected with the same dose and route of a separate 
stock of the same isolate of ZIKV, which was passaged an additional time in Vero cells. The limit of detection 
of approximately 15 copies per milliliter of plasma is shown as a horizontal line. Viremia remained detectable 
beyond 21 days in several pregnant females but these values are cut from panel (B) for clarity. (E) Area under 
the curve analysis to assess total viremia in our infants relative to other animals in our studies. Data from the 
pregnant females includes all time points with viremia, including beyond day 21. (F) At necropsy, the presence 
of ZIKV viral RNA was assessed by qRT PCR from blood, CSF, and several brain sections as well as a lymph 
node from each animal.
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Figure 4. ZIKV-specific binding and neutralizing antibodies. (A) Neutralizing antibodies as assessed using 
a Plaque reduction neutralization test (PRNT). Shown are PRNT 80% values using plasma from both infants. 
Plasma samples with PRNT titers of <20 are reported at 20. Each sample was tested in duplicate; the average 
titer is shown. (B) Anti-ZIKV binding antibodies as assessed using a whole virion ELISA (WVE) test. Each 
sample was tested in duplicate and the average titer is shown. The lower limit of detection in this assay was 
determined to be 12.5 (horizontal line). (A,B) The infants were infected at 20 and 21 weeks of age but antibody 
responses post-infection are shown at time points expressed as weeks post infection, as indicated by the asterisk, 
for clarity.
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facilitate the development of dengue hemorrhagic fever in infants postnatally infected with a heterologous sero-
type of DENV43,44. Intriguingly, maternal anti-DENV antibodies have been shown to enhance ZIKV associated 
fetal disease in mice45 while administration of sub-neutralizing doses of the pan-flavivirus specific monoclonal 
antibody 4G2 to pregnant, immunocompetent, ZIKV infected mice resulted in enhanced neuropathological out-
comes in infants46. These published data suggest that maternally acquired heterotypic antibodies may enhance 
pathology associated with postnatal infection. Since our study used fully homologous virus to infect both the 
dams and their infants, it is possible our results would have been different had we infected the infants with a 
heterologous virus.
Here, we report the results of a small pilot study describing results from two infant macaques born to dams 
infected with ZIKV during the third trimester. One dam had relatively high levels of viral RNA detected in amni-
otic fluid near full gestation, possibly suggesting fetal infection, but no virus was detected in either infant after 
birth. A recent study of two infants infected with ZIKV after birth showed significant impairment of cognitive 
function and reduced reaction to fearful stimuli32, which the authors interpreted as a likely consequence of infec-
tion during early infancy. Our behavioral analyses detected no indications that infant development was negatively 
affected by the maternal infection status. Both infants showed levels of orientation, state control, motor acuity, 
and activity soon after birth that were largely within normal ranges and at 16 and 20 weeks showed normal 
cognitive and motor abilities. Both also showed lower than normal temperament, however, this measurement is 
highly variable in healthy infants and could be a result of the small sample size. Taken together, behavioral data 
from our infants showed no direct evidence of infection nor negative consequences due to infection of their dams 
during pregnancy. Our data and that from a published study32 cannot be compared for several reasons. Most sig-
nificantly, the infants in that study were observed for behavioral abnormalities after direct infection early in life, 
whereas our analyses were conducted on infants born to infected mothers, but prior to experimental infection at 
approximately five months of age. Finally, comparisons of viral kinetics and tissue dissemination are also limited 
due to the use of similar but non-identical viruses and at different doses. We infected our infants with 104 pfu of 
ZIKV whereas they used 105. It’s not known if such a difference could explain different viral kinetics seen in their 
study. However, we propose the presence of detectable maternal antibodies in our infants at the time of infection 
likely limited viral replication in blood and reduced viral dissemination, but we cannot state this with certainty 
without proper controls.
Both infants in our study harbored detectable levels of anti-ZIKV neutralizing antibodies at birth that declined 
between one- and four-months post birth. We interpret these data to suggest these antibodies were passively 
acquired from the dams as opposed to mounted directly by the infants. ZIKV-binding IgG also declined after 
birth but remained detectable between at five months of age, when we experimentally infected the animals with 
ZIKV. Upon ZIKV infection, both exhibited low peak serum viremia that was rapidly cleared resulting in no 
evidence of infection in neurological tissues or CSF, but viral RNA was detected in the only lymph node sampled. 
Other potentially important tissues, including spleen and additional lymph nodes, were not sampled, so larger 
conclusions on viral dissemination cannot be drawn. These data contrast with published data on postnatally 
ZIKV-infected infant macaques32 born to ZIKV naïve dams, but comparisons with this and the previous study are 
limited due to the use of different viruses and methodologies.
ZIKV binding antibodies, likely maternal in origin, remained detectable from birth until the day of infection, 
possibly mediating some level of viral control. It is also possible neutralizing maternal antibodies, though unde-
tectable in the PRNT assay at the time of infection, remained at a sufficient level to provide partial protection to 
the infants. In support of this possibility, infant F10, who retained detectable levels of neutralizing antibodies 
longer than F09, also had the lowest peak of viremia in the blood and then mounted a weaker and slower de 
novo antibody response to the virus and had less virus in lymph nodes. Alternatively, maternal antibodies may 
mediate protection via non-neutralizing functions, such as antibody-dependent cellular cytotoxicity (ADCC) 
and antibody-dependent cellular phagocytosis (ADCP). Maternal antibodies with ADCC function have been 
detected in infants born to HIV infected mothers47. Both infants harbored viral RNA in axillary lymph nodes at 
necropsy, suggesting that even a brief period of serum viremia is sufficient for tissue dissemination, which may 
result in consequences not tested in our study, including inflammation.
Our data provide an important body of data on the study of developing infants infected postnatally with ZIKV. 
The results of this small pilot study should be interpreted with caution. Our sample size was small and lacked an 
important control group of infants born to healthy, ZIKV naïve mothers. Further, we infected the infants with 
virus that was fully homologous to the strain used to infect their dams so our data cannot be used to infer poten-
tial outcomes when infants are infected with heterologous isolates of the virus. Similar studies using heterologous 
virus could demonstrate differing outcomes.
Taken together, our data suggest that infants born healthy to ZIKV infected mothers harbor maternal antibod-
ies that may provide a modest but important level of protection from ZIKV that dampened acute viral loads and 
limited tissue dissemination of the virus. This study, along with others, provide a framework for the assessment of 
the vulnerability of infants exposed postnatally to flaviviruses.
Materials and Methods
cohort. All macaques used in this study were housed at the Tulane National Primate Research Center 
(TNPRC), which is fully accredited by AAALAC (Association for the Assessment and Accreditation of Laboratory 
Animal Care) International, Animal Welfare Assurance No. A3180-01. Animals were cared for in accordance with 
the NRC Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. Animal experiments 
were approved by the Institutional Animal Care and Use Committee (IACUC) of Tulane University (protocol 
P0336). Two adult female, purpose bred Indian rhesus macaques, were identified as pregnant and subsequently 
assigned to the study. These macaques were infected with ZIKV during early third trimester. Infants were deliv-
ered via caesarian section at approximately gestational day 155 (full term) and housed in a primate nursery until 
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5 months of age and then infected with ZIKV subcutaneously with 104 PFU of a Brazilian isolate (Rio-U1/2016 
GenBank KU926309), which was passage twice in Vero cells post-virus isolation, which is the same dose we 
have used in our previous studies23 and similar to those used in several nonhuman primate ZIKV studies, which 
inoculated with doses ranging from 103 48 to 105 32,49. The animals were euthanized fourteen days later for tissue 
harvest and pathological assessment.
Viral load measurements. Viral RNA was amplified and quantified based on a previously described 
assay23. Briefly, RNA was manually extracted from 200 ul fluid samples (CSF or blood serum) unless sample vol-
ume was limiting using the High Pure Viral RNA Kit (Roche). RNA was then subjected to reverse transcription 
and quantitative PCR using primers (Forward 5′ TTG AAG AGG CTG CCA GC 3′; Reverse 5′CCC ACT GAA 
CCC CAT CTA TTG 3′) and a double-quenched (ZEN/Iowa Black FQ) and fluorescently labeled (FAM) probe 
(5′TGA GAC CCA GTG ATG GCT TGA TTG C 3′) (all oligos were from Integrated DNA Technologies) on an 
Applied Biosystems 7900 instrument. For absolute quantification, a standard curve was generated with every 
run generated using tenfold serial dilutions of a 401 bp in vitro RNA transcript encoding the ZIKV capsid gene 
starting at approximately 1 × 108 RNA copies per 30 ul reaction. The limit of detection was approximately 15 viral 
RNA copies/ml. ZIKV-positive and -negative samples were included in every run.
Plaque reduction neutralization test (PRNT) 80 measurements. Neutralizing antibody quantifi-
cation by plaque reduction neutralization test (PRNT) endpoint 80% PRNT titers were determined in infant 
macaque plasma, where each sample was tested in duplicate. Plasma samples were heated to 56 °C for 30 min-
utes to inactivate complement, serially 2-fold diluted starting at 1:10 (1:20 final virus:plasma dilution) in 150 µl 
Dulbecco’s Modified Eagle Medium (DMEM) with 2% fetal bovine serum, and then incubated for 1 hour at 37 °C 
with approximately 100 plaque forming units of a 2015 Brazilian ZIKV strain (SPH2015, GenBank accession 
number: KU321639.1) from a third Vero cell passage. After 1 hour, virus-antibody or virus-only mixtures were 
overlaid on confluent African Green Monkey Kidney (Vero) cell monolayers and incubated for 1 hour with rock-
ing every 15 minutes. The plaques developed under 0.5% agar overlays in DMEM were counted after 7 days under 
crystal violet staining. Dilutions of plasma that caused a > 80% reduction in the number of plaques, as compared 
with negative controls (DMEM only), were considered positive. The reciprocal of the highest dilution of plasma 
(represented as the mean final virus-serum dilution from both replicates) that inhibited at least 80% of plaques is 
reported as the antibody titer.
Detection of ZIKV-specific IgG in rhesus plasma. High-binding 96-well ELISA plates (Greiner; 
Monroe, NC) were coated with 40 ng/well of 4G2 monoclonal antibody, produced in a mouse hybridoma cell 
line (D1-4G2-4-15,ATCC; Manassas, VA), diluted to 0.8 ng/uL in 0.1M carbonate buffer (pH 9.6) and incubated 
overnight at 4 °C. Plates were blocked in 1X Tris-buffered saline containing 0.05% Tween-20 and 5% normal 
goat serum for 1 hour at 37 °C, followed by an incubation with diluted ZIKV (strain PRVABC59, BEI; Manassas, 
VA) for 1 hour at 37 °C. Optimal virus dilution was determined by whole virion ELISA (WVE) and a 1:5 dilution 
was used in these assays. Plasma samples were tested at a dilution of 1:12.5-204,800 in serial 4-fold dilutions and 
incubated for 1 hour at 37 °C, along with a ZIKV-specific monoclonal antibody, H24 (10 ug/mL), isolated from a 
ZIKV-infected rhesus macaque. Horseradish peroxidase (HRP)-conjugated mouse anti-monkey IgG secondary 
antibody (Southern BioTech; Birmingham, AL) was used at a 1:4,000 dilution and incubated at 37 °C for 1 hour, 
followed by the addition of SureBlue Reserve TMB Substrate (KPL; Gaithersburg, MD). Reactions were stopped 
by Stop Solution (KPL; Gaithersburg, MD) after a 7-minute incubation per plate in the dark. Optical density 
(OD) was detected at 450 nm on a Victor X Multilabel plate reader (PerkinElmer; Waltham, MA). Binding was 
considered detectable if the sample OD value at the lowest dilution was greater than that of the Background OD, 
defined as the OD value of the negative control at the lowest dilution plus 2 x standard deviations (SD). For sam-
ples considered positive, their OD values for the serial dilution were entered into Prism v8 (GraphPad Software; 
San Diego, CA) to determine the 50% effective dilution (ED50). The ED50 was calculated by first transforming 
the x-axis values, the dilution series 12.5-204,800 4F, into Log10. The transformed data was then analyzed using 
a sigmoidal dose-response nonlinear regression model. Any sample considered negative was assigned an ED50 
of 12.5, the lowest dilution tested, because ED50 cannot be accurately calculated below the lowest dilution tested. 
Zika-specific IgG binding was reported in Log10 ED50.
Behavioral observations. We employed two age-appropriate behavioral tests that are designed for use in 
infant nonhuman primates. These neurobehavioral tests were performed to identify any effects of potential pre-
natal exposure to ZIKV and were modelled upon testing tools used for human infants50,51 and adapted for use in 
nonhuman primates52. Tests were administered every two weeks, from 14 days of age until euthanasia at 20 (F10) 
or 21 weeks (F09). Each infant’s scores were compared descriptively against the mean and standard deviation 
across seven control animals reared in the same fashion and tested by the same behavioral technician. Data for 
control animals were available at three time points.
Infant neurobehavioral assessment scale (NBAS). This test is adapted for nonhuman primates from 
the Brazelton Neonatal Behavioral Assessment Scales used with humans53. This test is valid for infants during the 
first four weeks of life. The scale consists of a 20-minute battery of tests that assess an infant’s motor functioning, 
temperament, and interactive skills54–56. In each test, an animal was scored using a 3- to 5-interval scale, depend-
ing on the test element. Test elements were categorized for analysis following factor analyses by Schneider et al. 
(1991)56: Orientation (visual orientation, visual follow, duration of looking, attention), State control (initial state, 
consolability, struggle during test, predominant state), Motor maturity (head posture prone, head posture supine, 
labyrinthian righting, speed of responses to tester), and Activity (motor activity, coordination, spontaneous crawl, 
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proportion of test active). For each category, scores for individual tests were averaged for analysis. Study subjects 
were compared with age-matched controls at 14 days of age.
Bayley test of infant development. This test originally was developed for use with human infants but 
modified for nonhuman primates ranging in age from 1 month to 1 year-old57. The 10-minute evaluation consists 
of cognitive, motor, and temperament tests. Briefly, each subject is held on a table by one examiner and another 
places test items in front of the subject and records their responses. Separate motor and behavioral test variables 
were collapsed into 3 categories for analysis: Cognition (lift cup, uncover toy, pull string, remove treat from bottle, 
object orientation, goal directedness), Motor abilities (labyrinthian righting, muscle tonus, fine motor coordina-
tion), and Temperament (response to examiner, irritability, activity, response intensity, struggle, consolability). 
Each test element was scored using a 4–5 interval scale depending on the test element. Scores within a category 
were summed for analysis. Tests were conducted monthly between 3 months of age through the end of the study. 
Study subjects were compared age-matched control animals.
Data Availability
All data is available from the corresponding author on request.
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